SEAK Therapeutics

SEAK Therapeutics is a preclinical-stage biotechnology startup founded in 2018 as a spin-off from the University of Tennessee Health Science Center (UTHSC). The company focuses on the discovery and development of molecularly targeted small-molecule therapeutics for pediatric and adult cancers, as well as neurological disorders. Its pipeline includes JW-65, a selective TRPC3 ion channel inhibitor being developed for epilepsy and seizures, which has been licensed to a leading biotech firm. Additionally, SEAK is advancing SEAK193, a brain-penetrable antimitotic agent targeting tubulin for breast cancer brain metastasis, and SEAK-114, a dual MDM2/XIAP inhibitor for pediatric cancers. The company's research has been primarily funded through non-dilutive federal SBIR and STTR grants from the National Institutes of Health (NIH).